Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will

Avacta Group has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva. The

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that it has entered into a collaboration with the Liverpool School of Tropical Medicine (LSTM) to clinically validate

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that it has appointed BBI Solutions, part of BBI Group, to manufacture the saliva-based rapid SARS-CoV-2 antigen test

Coronaviruses are a large family of viruses that cause illnesses like the common cold, but can also cause more severe diseases such as Middle East Respiratory Syndrome (MERS) and Sever

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell Therapeutics, the joint venture

Testing Therapies, Antivirals and Vaccines Avacta Group has partnered with the U.K. government’s CONDOR program to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry laboratory assay developed with

Sewage monitoring is being trialled as a way to spot new outbreaks of coronavirus, and three UK companies have now joined forces to try to develop a probe for this

All health and care staff should be routinely tested for Covid-19 once or twice a week, according to one of the UK’s most eminent scientists, Sir Paul Nurse, whose team’s